Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.

导出 LinkOut

翻译打印收藏纠错

作者： Rebekah H,Borse ^[1] ; Sumesh,Kachroo ^[2] ; Chloe,Brown ^[3] ; Eilish,McCann ^[3] ; Ralph P,Insinga ^[2]

作者单位： Merck & Co., Inc., Kenilworth, NJ, USA. rebekah.borse@merck.com. ^[1] Merck & Co., Inc., Kenilworth, NJ, USA. ^[2] Merck Sharp & Dohme, Hoddesdon, UK. ^[3]

关键词 Ankylosing spondylitis Cost-effectiveness Decision tree Golimumab Markov model Non-radiographic axial spondyloarthritis Scotland Tumor necrosis factor inhibitors

DOI 10.1007/s40744-018-0108-4

PMID 29633197

发布时间 2020-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Rheumatology and therapy

2018年5卷1期

57-73页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.

Rheumatology and therapy

相似文献

Rheumatology and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.

Rheumatology and therapy

相似文献

Rheumatology and therapy

相关期刊

检索历史清除